EARS News and Press, Auris Medical Holding AG From 03/11/19

Zug, Switzerland, March 11, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the publication of an article that presen...

Zug, Switzerland, March 07, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it will provide a business update an...

Hearing Requested to Present Compliance Plan Zug, Switzerland, February 8, 2019 - Auris Medical Holding AG (Nasdaq: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, toda...

Zug, Switzerland, February 1, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the complete repayment of its loan faci...

Move to Bermuda will enhance corporate flexibility, reduce costs and provide better alignment with U.S. corporate law   Subject to approval by extraordinary general meeting of shareholders Zug, Switzerland, January 29, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical...

NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued to ease. The Dow Jones Industrial Average gained 1.06 percent to close at 25,380...

LONDON, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Auris Medical (EARS) is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The company’s primary focus is on the development of intranasal betahistine for the treatment of acute ...